Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients

This is a multicenter phase II study concerning patients with high-grade bone sarcoma (HGBS) without complete remission after standard treatment at diagnosis or at relapse. Patients will be treated with regorafenib + best supportive care (BSC) for a maximum of 12 months as maintenance therapy after standard line therapy completion. Progression free rate (PFR) data will be collected and analysed for all included patients to evaluate if regorafenib + BSC can be considered as an interesting treatment for further investigations in this indication.

Trial Details

NCT ID
NCT04698785
Phase
PHASE2
Sponsor
Centre Leon Berard
Status
RECRUITING
Cancer Type
Osteosarcoma Sarcoma
Interventions
  • Treatment by regorafenib and best supportive care
Locations (sample)
  • Besançon, France|47.24878,6.01815
  • Bordeaux, France|44.84124,-0.58046
  • Dijon, France|47.31344,5.01391
  • Lille, France|50.63391,3.05512
  • Lyon, France|45.74906,4.84789

Key Eligibility Criteria

  • I1. Age ≥ 12 years at the day of consenting to the study;
  • I2. Patients must have histologically confirmed high-grade sarcomas of bone primary localisation, including but not limited to: Osteosarcomas, Ewin…
  • I3. Evaluable residual disease not amenable to resection after multimodal treatment principles either at diagnosis (after standard multimodal treat…
  • I4. Non progressive disease (defined by the investigator according to the RECIST version 1.1 Appendix 1) at study entry;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Osteosarcoma Sarcoma Trials on Trialify →